Fennec Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 12, 2026
Globe Newswire•06/11/2026•05:50 ET
0
Key Highlights
- ➤Q3 2026 results scheduled for November 12 before U.S. market opening
- ➤Management will host an 8:30 a.m. Eastern conference call and webcast
- ➤Fennec commercializes PEDMARK for cisplatin-induced ototoxicity risk reduction
- ➤Norgine exclusively commercializes PEDMARQSI across Europe, U.K., Australia and New Zealand
RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2026 financial results before the opening of the U.S. financial markets on Thursday, November 12, 2026. Management will host a conference call and webcast that day to discuss the Company’s financial and business results.
Date: Thursday, November 12, 2026 Time: 8:30 a.m. Eastern Time Webcast Link: https://edge.media-server.com/mmc/p/vuhn59ek Participant Link: https://register-conf.media-server.com/register/BIa5435e66b82346329a08be7e156e3eac
Get started
Create a free account to read the full story.